Patent intelligence · US
US 2016175302
MASITINIB FOR TREATING GASTRIC CANCER
MASITINIB FOR TREATING GASTRIC CANCER
Patent details — US 2016175302
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 23, 2016
- Expiration
- Jun 18, 2036
- Applicant
- AB SCIENCE [FR]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 475 A I, A61K 31/ 496 A I, A61K 31/ 513 A I
Quick answer
US 2016175302 (MASITINIB FOR TREATING GASTRIC CANCER) is held by AB SCIENCE [FR]. Status: granted. Granted Jun 23, 2016. Expires Jun 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AB SCIENCE [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 475 A I, A61K 31/ 496 A I, A61K 31/ 513 A I, A61K 31/ 519 A I, A61K 31/ 4745 A I
More from AB SCIENCE [FR]
Related pharmaceutical patents in our USPTO index.
-
WO 2025027051
INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
granted -
WO 2024175803
COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES
granted -
WO 2024146923
INHIBITEURS DE POLYMÉRISATION DE TUBULINE
granted -
CN 117980330
Homodimeric peptides and antibodies comprising same
granted -
CA 3217490
MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION
granted -
WO 2022234069
NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
granted -
CA 3201259
MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
granted -
CA 3174748
UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)
granted
Frequently asked questions
What is US patent 2016175302?
US 2016175302 (MASITINIB FOR TREATING GASTRIC CANCER) is held by AB SCIENCE [FR]. Status: granted. Granted Jun 23, 2016. Expires Jun 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2016175302?
AB SCIENCE [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2016175302 expire?
Our index shows an expiration date of Jun 18, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.